Human Papilloma Virus Clinical Trial
— MOUTHOfficial title:
Impacting the Oral HPV Continuum: MOUTH Study (Men and Women Offering Understanding of Throat HPV)
| Verified date | March 2024 |
| Source | Johns Hopkins Bloomberg School of Public Health |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational [Patient Registry] |
This study will screen people for oncogenic oral Human Papillomavirus (HPV) infection and antibodies to form a cohort of people who may be at increased risk of HPV-oropharyngeal cancer (HPV-OPC). The investigators will follow these individuals prospectively to evaluate oncogenic oral HPV persistence, risk factors, and biomarkers for persistence.
| Status | Active, not recruiting |
| Enrollment | 1500 |
| Est. completion date | June 2028 |
| Est. primary completion date | April 2025 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Participants in the Phase 1 Screening Inclusion criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: - 18 and older (enrollment at most sites will be restricted to 30 and older since this demographic has the highest prevalence of infection; however, individuals and/or partners of someone with an HPV-related cancer, for example, are at increased risk so will be enrolled in the larger age range). - Willing to be contacted to arrange follow-up visits, if determined to be eligible for phase 2 - Ability to understand and the willingness to sign a written informed consent document In addition, individuals must meet at least one of the following criteria: - Male, aged 30 and older, with 2 or more lifetime oral sex - History of anal or genital dysplasia or cancer - Partners of someone with an HPV-related cancer (HPV-positive OPC, anal cancer or genital cancer) - Known oncogenic HPV-positive biomarker from prior studies or testing, regardless of number of partners. Exclusion criteria: An individual who meets any of the following criteria will be excluded from participation in this study: - Presence of medical or psychiatric condition affecting ability to give voluntary, informed consent. - Participants who do not speak English cannot enroll because the consent and study survey are only available in English. However, if there is a hearing, literacy or minor fluency issue and the participant requests assistance from a family member or the study coordinator, this individual may still enroll and receive this assistance to ensure they fully hear and understand everything being asked. - History of head and neck cancer Participants in the Phase 2 Follow-Up Inclusion criteria: - Oncogenic oral HPV infection and/or HPV serum oncogenic antibodies detected in phase 1 - Willingness to complete annual follow up visits Exclusion criteria: • Unable to complete annual follow up visits |
| Country | Name | City | State |
|---|---|---|---|
| United States | Johns Hopkins Hospital | Baltimore | Maryland |
| Lead Sponsor | Collaborator |
|---|---|
| Johns Hopkins Bloomberg School of Public Health | Icahn School of Medicine at Mount Sinai, National Institute of Dental and Craniofacial Research (NIDCR) |
United States,
D'Souza G, Clemens G, Troy T, Castillo RG, Struijk L, Waterboer T, Bender N, Pierorazio PM, Best SR, Strickler H, Wiley DJ, Haddad RI, Posner M, Fakhry C. Evaluating the Utility and Prevalence of HPV Biomarkers in Oral Rinses and Serology for HPV-related — View Citation
D'Souza G, Tewari SR, Troy T, Waterboer T, Struijk L, Castillo R, Wright H, Shen M, Miles B, Johansson M, Robbins HA, Fakhry C. Prevalence of oral and blood oncogenic human papillomavirus biomarkers among an enriched screening population: Baseline results — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Oncogenic oral HPV infection present or absent in oral rinse sample | To explore the effects of biologic (microbiome, oral immune response, biologic sex) risk factors for oncogenic oral HPV persistence | Baseline to end of four year follow-up and data abstraction/linkage. | |
| Secondary | HPV16 E6 antibodies present or absent in serum sample | To explore whether E6 and E7 seropositivity (to HPV16 or any oncogenic HPV) are markers for oncogenic oral HPV persistence among high-risk groups | Baseline to end of four year follow-up and data abstraction/linkage. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05329961 -
Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study
|
Early Phase 1 | |
| Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
| Active, not recruiting |
NCT04199078 -
Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.
|
N/A | |
| Recruiting |
NCT05566106 -
Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV
|
||
| Not yet recruiting |
NCT06436274 -
Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.
|
Phase 4 | |
| Not yet recruiting |
NCT06229353 -
Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department
|
||
| Completed |
NCT01757392 -
Candin Safety & Efficacy Study for the Treatment of Warts
|
Phase 2 | |
| Active, not recruiting |
NCT04716127 -
A Proximity-incentive Strategy for Cervical Cancer Screening
|
N/A | |
| Recruiting |
NCT05210348 -
Clinical Evaluation of Detection of High Risk HPV in Urine
|
||
| Recruiting |
NCT05835947 -
Anal Cancer Risk In Women
|
||
| Not yet recruiting |
NCT03947775 -
HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL
|
Phase 2 | |
| Terminated |
NCT03404310 -
Zinc Sulfate for Human Papillomavirus (HPV)
|
N/A | |
| Recruiting |
NCT03302858 -
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand
|
Phase 2 | |
| Completed |
NCT03082950 -
HPV Infections, Cancer of the Vulva and Therapeutical Success
|
||
| Active, not recruiting |
NCT04950101 -
Prevalence of Anal High-risk Human Papilloma Virus Infection and Abnormal Anal Cytology in Men Who Have Sex With Men Using Pre Exposure Prophylaxis
|
N/A | |
| Recruiting |
NCT05146895 -
A Cohort Study of Hyperthermia and Imiquimod for the Treatment of Flat Warts
|
N/A | |
| Completed |
NCT04002154 -
Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV
|
N/A | |
| Recruiting |
NCT04232917 -
Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections.
|
Phase 4 | |
| Active, not recruiting |
NCT03729518 -
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
|
N/A | |
| Recruiting |
NCT05640700 -
Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia
|